Neumora Therapeutics (NMRA) Set to Announce Earnings on Thursday

Neumora Therapeutics (NASDAQ:NMRA) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.1966) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. On average, analysts expect Neumora Therapeutics to post ($0.84) EPS for the current fiscal year and ($0.69) EPS for the next fiscal year.

Neumora Therapeutics Price Performance

Neumora Therapeutics stock opened at $0.57 on Wednesday. Neumora Therapeutics has a one year low of $0.32 and a one year high of $3.65. The business has a fifty day moving average price of $0.75 and a 200-day moving average price of $1.76. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 1.19.

Insider Transactions at Neumora Therapeutics

In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 21,055 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $1.60, for a total value of $33,688.00. Following the sale, the insider directly owned 48,750 shares in the company, valued at $78,000. This represents a 30.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 453,833 shares of company stock valued at $701,219. Corporate insiders own 26.94% of the company’s stock.

Analyst Ratings Changes

NMRA has been the topic of a number of analyst reports. Weiss Ratings upgraded Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 25th. HC Wainwright reissued a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. Wall Street Zen downgraded Neumora Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 10th. Finally, Royal Bank Of Canada reduced their target price on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.57.

About Neumora Therapeutics

Neumora Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. The company combines neuroscience, data science and machine-learning technologies to identify disease mechanisms, discover potential therapies and develop more targeted medicines for patients with neurological and neuropsychiatric disorders.

Neumora’s pipeline has included navacaprant, also known as NMRA-140, an investigational selective kappa opioid receptor antagonist being studied for major depressive disorder and related symptoms such as anhedonia, or the loss of interest and pleasure.